Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7819MR)

This product GTTS-WQ7819MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7819MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10507MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ9497MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ7620MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN1029
GTTS-WQ12918MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ14655MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ1355MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-874
GTTS-WQ13282MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ3690MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 2287409
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW